Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $51 price target.
Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rat...
mmunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD tr...
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimm...
UBS analyst Colin Bristow maintains Immunovant (NASDAQ:IMVT) with a Buy and lowers the price target from $42 to $41.
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and lowers the price target from $51 to $46.
Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.
